Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23747810 | 1.00 | RAB9A (0.53) | RAB9APOLBNPC1MAOBALDH1A1 | |
| SCHEMBL26100411 | 1.00 | RAB9A (0.53) | RAB9APOLBNPC1MAOBALDH1A1 | |
| SCHEMBL26102225 | 0.89 | RAB9A (0.53) | RAB9APOLBNPC1NAMPTKMT2A | |
| SCHEMBL26547014 | 0.89 | RAB9A (0.53) | RAB9APOLBNPC1NAMPTKMT2A | |
| SCHEMBL26547010 | 0.89 | RAB9A (0.53) | RAB9APOLBNPC1NAMPTKMT2A | |
| SCHEMBL23747772 | 0.89 | RAB9A (0.55) | RAB9APOLBNPC1MAOBALDH1A1 | |
| SCHEMBL30361379 | 0.88 | RAB9A (0.54) | RAB9APOLBNPC1MAOBALDH1A1 | |
| SCHEMBL26547117 | 0.88 | RAB9A (0.54) | RAB9APOLBNPC1MAOBALDH1A1 | |
| SCHEMBL26102371 | 0.86 | RAB9A (0.57) | RAB9APOLBNPC1MAOBALDH1A1 | |
| SCHEMBL23747816 | 0.86 | SMN1; SMN2 (0.57) | RAB9APOLBNPC1ALDH1A1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | RAB9A 807/4885POLB 4018/4885NPC1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.